UNIVERSITY OF WASHINGTON

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1861-01-01

Employees: 10K

Market Cap: -

Website: https://www.cs.washington.edu

Clinical Trials

Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer

Phase 1

Completed

Conditions: Male Breast Cancer
Stage II Breast Cancer
Stage IIIA Breast Cancer
Stage IV Breast Cancer
Stage IIIB Breast Cancer
Recurrent Breast Cancer
HER2-positive Breast Cancer
Stage IIIC Breast Cancer

Interventions: Biological: HER-2/neu peptide vaccine
Drug: rintatolimod
Biological: sargramostim

First Posted Date: 2011-05-18

Last Posted Date: 2020-02-10

Lead Sponsor: University of Washington

Target Recruit Count: 50

Registration Number: NCT01355393

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Improving Care Provided to Patients Treated in a Level 1 Trauma Center Post-suicide Attempt

Phase 1

Completed

Conditions: Suicidal Ideas

Interventions: Behavioral: Brief Intervention for Suicidality

First Posted Date: 2011-05-18

Last Posted Date: 2015-03-10

Lead Sponsor: University of Washington

Target Recruit Count: 40

Registration Number: NCT01355848

Locations: 🇺🇸
Harborview Medical Center, Seattle, Washington, United States

Piloting Acute Care to Primary Care Linkage of Safety Net Patients

Phase 1

Terminated

Conditions: Posttraumatic Stress Disorder

Interventions: Behavioral: Cognitive Behavioral Therapy
Behavioral: Standard Care Control
Behavioral: Motivational Interviewing
Drug: FDA-Approved Anti-Anxiety Medications

First Posted Date: 2011-05-04

Last Posted Date: 2021-03-10

Lead Sponsor: University of Washington

Target Recruit Count: 4

Registration Number: NCT01347541

Locations: 🇺🇸
Harborview Medical Center, Seattle, Washington, United States

Randomized Trial to Evaluate Suppressive Effect of High-Dose Valacyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2

Phase 4

Completed

Conditions: Genital Herpes

Interventions: Drug: Valacyclovir

First Posted Date: 2011-05-03

Last Posted Date: 2017-03-09

Lead Sponsor: University of Washington

Target Recruit Count: 50

Registration Number: NCT01346475

Locations: 🇺🇸
University of Washington Virology Research Clinic, Seattle, Washington, United States

TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck

Phase 1

Completed

Conditions: Recurrent Verrucous Carcinoma of the Oral Cavity
Tongue Cancer
Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity
Recurrent Squamous Cell Carcinoma of the Nasopharynx
Stage III Squamous Cell Carcinoma of the Hypopharynx
Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity
Stage III Squamous Cell Carcinoma of the Oropharynx
Stage IVB Verrucous Carcinoma of the Larynx
Stage IVC Verrucous Carcinoma of the Oral Cavity
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma